eMedicine Specialties > Vascular Surgery > Medical Topics

Superior Vena Cava Syndrome

Todd A Nickloes, DO, Assistant Professor of Surgery, Division of Trauma/Critical Care, University of Tennessee Medical Center
LaMar O Mack, MD, Staff Physician, Department of Surgery, University of Tennessee Medical Center; Andre M Kallab, MD, Clinical Associate Professor of Oncology, Medical College of Georgia; Consulting Staff, Department of Oncology, Northeast Georgia Diagnostic Clinic

Updated: Oct 28, 2009

Introduction

Background

Superior vena cava syndrome (SVCS) is obstruction of blood flow through the superior vena cava (SVC). It is a medical emergency and most often manifests in patients with a malignant disease process within the thorax. A patient with superior vena cava syndrome (SVCS) requires immediate diagnostic evaluation and therapy.

William Hunter first described the syndrome in 1757 in a patient with syphilitic aortic aneurysm.¹ In 1954, Schechter reviewed 274 well-documented cases of superior vena cava syndrome (SVCS) reported in the literature; 40% of them were due to syphilitic aneurysms or tuberculous mediastinitis.² In more recent times, these infections have gradually decreased as the primary cause of superior vena cava (SVC) obstruction. Lung cancer, particularly adenocarcinoma, is now the underlying process in approximately 70% of the patients with superior vena cava syndrome (SVCS).^3,4,5 However, up to 40% of the causes are due to nonmalignant causes.⁶

Superior vena cava syndrome (case 1). The patient was a 35-year-old man with a 3-year history of progressive upper-extremity and fascial swelling. The patient had undergone treatment for histoplasmosis in the past. CT scan shows a narrowed superior vena cava with adjacent calcified lymph nodes and posterior soft tissue thickening.

Pathophysiology

The superior vena cava (SVC) is the major drainage vessel for venous blood from the head, neck, upper extremities, and upper thorax. It is located in the middle mediastinum and is surrounded by relatively rigid structures such as the sternum, trachea, right bronchus, aorta, pulmonary artery, and the perihilar and paratracheal lymph nodes. It extends from the junction of the right and left innominate veins to the right atrium, a distance of 6-8 cm. It is a thin-walled, low-pressure, vascular structure. This wall is easily compressed as it traverses the right side of the mediastinum.⁷

Obstruction of the superior vena cava (SVC) may be caused by neoplastic invasion of the venous wall associated with intravascular thrombosis or, more simply, by extrinsic pressure of a tumor mass against the relatively fixed thin-walled superior vena cava (SVC). Postmortem examinations reveal that complete superior vena cava (SVC) obstruction is the result of intravascular thrombosis in combination with extrinsic pressure. Incomplete superior vena cava (SVC) obstruction is more often secondary to extrinsic compression without thrombosis. Other causes include compression by intravascular arterial devices. The incidence is on the rise in line with the increased usage of endovascular devices.⁴

An obstructed superior vena cava (SVC) initiates collateral venous return to the heart from the upper half of the body through 4 principal pathways. The first and most important pathway is the azygous venous system, which includes the azygous vein, the hemiazygous vein, and the connecting intercostal veins. The second pathway is the internal mammary venous system plus tributaries and secondary communications to the superior and inferior epigastric veins. The long thoracic venous system, with its connections to the femoral veins and vertebral veins, provides the third and fourth collateral routes, respectively.

Despite these collateral pathways, venous pressure is almost always elevated in the upper compartment if obstruction of the superior vena cava (SVC) is present. Venous pressure as high as 200-500 cm H₂ O has been recorded in patients with severe superior vena cava syndrome (SVCS).

Frequency

United States

Superior vena cava syndrome (SVCS) develops in 5-10% of patients with a right-sided malignant intrathoracic mass lesion. In 1969, Salsali and Cliffton observed superior vena cava syndrome (SVCS) in 4.2% of 4960 patients with lung cancer; 80% of the tumors inducing superior vena cava syndrome (SVCS) were of the right lung.⁸ In 5 large series of small cell lung cancer, 9-19% of patients demonstrated superior vena cava syndrome (SVCS). In 1987, Armstrong and Perez found superior vena cava syndrome (SVCS) in 1.9% of 952 patients with lymphoma.⁹

Mortality/Morbidity

• Survival in patients with superior vena cava syndrome (SVCS) depends mainly on the course of the underlying disease. No mortality, per se, results directly from mild venous congestion.
• In patients with benign superior vena cava syndrome (SVCS), life expectancy is unchanged.
• If superior vena cava syndrome (SVCS) is secondary to a malignant process, patient survival correlates with the histology of the tumor. Patients with signs and symptoms of laryngeal and cerebral edema have the most life-threatening manifestations of this syndrome and are in danger of sudden death. Clinical observations show that approximately 10% of patients with a bronchogenic carcinoma and 45% of patients with lymphoma treated with irradiation live at least 30 months. In contrast, patients with untreated malignant superior vena cava syndrome (SVCS) survive only approximately 30 days.⁵

Race

The frequency of superior vena cava syndrome (SVCS) in different races depends largely on the frequency of lung cancer and lymphomas in these populations.

Sex

• Malignant causes of superior vena cava syndrome (SVCS) are most commonly observed in males because of the high incidence of lung cancer in this population.
• In contrast, no sex difference is observed in cases related to benign causes.

Age

• Malignant causes of superior vena cava syndrome (SVCS) are predominantly observed in individuals aged 40-60 years.
• Benign causes account for most of the cases diagnosed in individuals aged 30-40 years.
• Obstruction of the superior vena cava (SVC) in the pediatric age group is rare and has a different etiologic spectrum.

Clinical

History

• Early in the clinical course, partial superior vena cava (SVC) obstruction may be asymptomatic, but more often, minor symptoms and signs are overlooked.
• As the syndrome advances toward total superior vena cava (SVC) obstruction, the classic symptoms and signs become more obvious.
  • Dyspnea is the most common symptom and is observed in 63% of patients with superior vena cava syndrome (SVCS).^7,10
  • Other symptoms include facial swelling, head fullness, cough, arm swelling, chest pain, dysphagia, orthopnea, distorted vision, hoarseness, stridor, headache, nasal stuffiness, nausea, pleural effusions, and light-headedness.^7,10,11

Physical

• The characteristic physical findings of superior vena cava syndrome (SVCS) include venous distension of the neck and chest wall, facial edema, upper extremity edema, mental changes, plethora, cyanosis, papilledema, stupor, and even coma.
• Bending forward or lying down may aggravate the symptoms and signs.

Causes

• More than 80% of cases of superior vena cava syndrome (SVCS) are caused by malignant mediastinal tumors.^12,13,14
  • Bronchogenic carcinomas account for 75-80% of all these cases, with most of these being small-cell carcinomas.³
  • Non-Hodgkin lymphoma (especially the large cell type) represents 10-15% of cases.
• Causes of superior vena cava syndrome (SVCS) appear similar to the relative incidence of primary lung and mediastinal tumors.
• Rare malignant diagnoses include Hodgkin disease, metastatic cancers,¹⁵ primary leiomyosarcomas of the mediastinal vessels, and plasmocytomas.^16,17,18
• Nonmalignant conditions causing superior vena cava syndrome (SVCS) include mediastinal fibrosis; vascular diseases such as aortic aneurysm, vasculitis, and arteriovenous fistulas; infections such as histoplasmosis, tuberculosis, syphilis, and actinomycosis; benign mediastinal tumors such as teratoma, cystic hygroma, thymoma, and dermoid cyst; cardiac causes, such as pericarditis and atrial myxoma; and thrombosis related to the presence of central vein catheters. These account for approximately 22% of the causes of superior vena cava syndrome (SVCS).^16,19,20,21

Differential Diagnoses

Other Problems to Be Considered

Aortic aneurysm

Workup

Imaging Studies

• Patients presenting with overt superior vena cava syndrome (SVCS) may be diagnosed by means of physical examination alone. However, subtle presentations require diagnostic imaging. Chest radiography may reveal a widened mediastinum or a mass in the right side of the chest. Only 16% of the patients studied by Parish and colleagues in 1981 had normal findings on chest radiography.¹⁹
• CT has the advantage of providing more accurate information on the location of the obstruction and may guide attempts at biopsy by mediastinoscopy, bronchoscopy, or percutaneous fine-needle aspiration.⁷
  • It also provides information on other critical structures such as the bronchi and the vocal cords.
  • The additional information is necessary because the involvement of these structures requires prompt action for relief of pressure.
• MRI has not been sufficiently investigated, but it appears promising.
  • It has several potential advantages over CT scanning, including the fact that it provides images in several planes of view and allows direct visualization of blood flow. Furthermore, MRI does not require iodinated contrast material. This is especially important when stenting is anticipated.²⁰
  • Disadvantages may include increased scanning time with attendant problems in patient compliance and increased cost.
• Invasive contrast venography is the most conclusive diagnostic tool.
  • It precisely defines the etiology of obstruction.
  • It is especially important if surgical management is being considered for the obstructed vena cava.
• Radionuclide technetium-99m venography is an alternative minimally invasive method of imaging the venous system. Although images obtained by this method are not as well defined as those achieved with contrast venography, they demonstrate potency and flow patterns.²²
• Gallium single-proton emission CT scanning may be of value in select cases.

Procedures

• Most patients with superior vena cava syndrome (SVCS) present before the primary diagnosis is established.
• Controversy often arises in the treatment of a patient with superior vena cava syndrome (SVCS) in regard to the need for pathologic confirmation of malignancy before the start of therapy.
• Treatment without an established diagnosis should be initiated only in patients with rapidly progressive symptoms or those in whom multiple attempts to obtain a tissue diagnosis have been unsuccessful.
• Fortunately, relatively noninvasive measures establish the diagnosis in a high percentage of patients with superior vena cava syndrome (SVCS).  
  • Sputum cytologic results are diagnostic in 68% of the cases, whereas biopsy of a palpable supraclavicular node is positive in 87%.²³
  • Bronchoscopy has a 60% success rate, while thoracotomy is 100% successful.²³
  • Open biopsy is rarely needed for diagnosis. Dosios et al showed that cervical mediastinoscopy and anterior mediastinoscopy are effective in establishing a histiologic diagnosis.²⁴

Treatment

Medical Care

The goals of superior vena cava syndrome (SVCS) management are to relieve symptoms and to attempt cure of the primary malignant process. Only a small percentage of patients with a rapid-onset superior vena cava (SVC) obstruction are at risk for life-threatening complications.¹⁷

• Patients with clinical superior vena cava syndrome (SVCS) often gain significant symptomatic improvement from conservative treatment measures, including elevation of the head of the bed and supplemental oxygen.²³
• Emergency treatment is indicated when brain edema, decreased cardiac output, or upper airway edema is present. Corticosteroids and diuretics are often used to relieve laryngeal or cerebral edema, although documentation of their efficacy is questionable.
• Radiotherapy has been advocated as a standard treatment for most patients with superior vena cava syndrome (SVCS). It is used as the initial treatment if a histologic diagnosis cannot be established and the clinical status of the patient is deteriorating; however, recent reviews suggest that superior vena cava syndrome (SVCS) obstruction alone rarely represents an absolute emergency that requires treatment without a specific diagnosis.^3,25
  • The fractionation schedule of radiation usually includes 2-4 large initial fractions of 300-400 cGy, followed by conventional fractionation of 150-200 cGy daily, to a total dose of 3000-5000 cGy. The radiation dose depends on tumor size and radioresponsiveness. The radiation portal should include a 2-cm margin around the tumor.
  • During irradiation, patients improve clinically before objective signs of tumor shrinkage are evident on chest radiography. Radiation therapy palliates superior vena cava (SVC) obstruction in 70% of patients with lung carcinoma and in more than 95% with lymphoma.
• In patients with superior vena cava syndrome (SVCS) secondary to non–small-cell carcinoma of the lung, radiotherapy is the primary treatment. The likelihood of patients benefiting from such therapy is high, but the overall prognosis of these patients is poor.²⁶
• Chemotherapy may be preferable to radiation for patients with chemosensitive tumors.²⁶
  • In 1983, Maddox and associates reported on 56 patients with small-cell lung cancer who presented with superior vena cava syndrome (SVCS). Correction of superior vena cava syndrome (SVCS) was obtained in 9 (56%) of 16 patients treated with radiation therapy alone, in 23 (100%) of 23 given chemotherapy, and in 5 (83%) of 6 who received combined therapy.²⁷
  • The most extensive experience in superior vena cava syndrome (SVCS) management secondary to non-Hodgkin lymphoma is reported from the M.D. Anderson cancer center. Patients were treated with chemotherapy alone, chemotherapy combined with radiation therapy, or radiation therapy alone. All patients achieved complete relief of superior vena cava syndrome (SVCS) symptoms within 2 weeks of the institution of any type of treatment. No treatment modality appeared to be superior in achieving clinical improvement.²⁸
• When superior vena cava syndrome (SVCS) is due to thrombus around a central venous catheter, patients may be treated with antifibrinolytics (eg, streptokinase, urokinase, recombinant tissue-type plasminogen activator) or anticoagulants (eg, heparin, oral anticoagulants). Removal of the catheter, if possible, is another option, and it should be combined with anticoagulation to avoid embolization.^7,21
• In a 1988 report, Adelstein et al discuss prophylaxis against embolic events in the presence of a superior vena cava (SVC) obstruction in the management of 25 patients with malignant superior vena cava syndrome (SVCS).²⁹
• Ten patients were retrospectively reviewed after having been diagnosed clinically without venography and treated without anticoagulation. Five thromboembolic complications occurred, 2 of which proved fatal.
• Fifteen patients were prospectively evaluated by means of angiography and then treated with anticoagulants. Angiographic evidence of intraluminal subclavian vein or superior vena cava (SVC) thrombosis was found in 5 of these patients, and no thromboembolic complications occurred.
• Of the 20 patients who were ultimately given anticoagulation therapy, 2 had fatal intracranial hemorrhages.
• The authors suggested the need for randomized prospective trials if the role of venography and anticoagulation in this syndrome is to be determined.²⁹

Surgical Care

• Surgical bypass of the superior vena cava (SVC) may be a useful way to palliate symptoms in carefully selected patients.
  • Indications to proceed with such procedures are much less clear.
  • For the most part, these are patients with advanced intrathoracic disease amenable only to palliative therapy (ie, after failure of radiation therapy and chemotherapy).
  • Patients with benign disease appear to be the best candidates for bypass.^30,31
• Superior vena cava (SVC) stenting can provide rapid symptomatic relief within few days in most patients with superior vena cava syndrome (SVCS).
  • Superior vena cava (SVC) stenting may provide relief of severe symptoms for patients while the histological diagnosis of the malignancy causing the obstruction is being actively pursued.^20,25,31
  • Stenting may also be indicated in patients in whom chemotherapy or radiation has failed.^32,33,34
  • Some literature recommends stenting as a first-line treatment to be performed early in the management of superior vena cava syndrome (SVCS).^32,33,34
  • Cases of excimer laser removal of pacemaker leads followed by venoplasty and stenting have been reported.³⁵

Consultations

• Thoracic surgeon
• Hematologist/oncologist
• Radiation therapist
• Interventional radiologist

Medication

The goals of pharmacotherapy are to reduce morbidity and to prevent complications.

Corticosteroids

These agents reduce swelling in patients with cerebral or laryngeal edema.

Dexamethasone (Decadron, Dexasone)

Important therapeutic agent in a number of malignant diseases. Exerts biologic action predominately by binding to glucocorticoid receptor. For symptomatic management in tumor-associated edema.

Dosing

Adult

8-40 mg IV once initially, followed by 4-6 mg IV/PO q6-8h

Pediatric

Not established

Interactions

Effects decrease with coadministration of barbiturates, phenytoin, and rifampin; decreases effect of salicylates and vaccines used for immunization

Contraindications

Documented hypersensitivity; active bacterial or fungal infection

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Caution in tuberculosis (and other infections), hypothyroidism, ocular herpes simplex, peptic ulcer disease, hypertension, osteoporosis, diabetes mellitus, ulcerative colitis, and diverticulitis; increases risk of multiple complications, including severe infections; monitor adrenal insufficiency when tapering drug; abrupt discontinuation of glucocorticoids may cause adrenal crisis; hyperglycemia, edema, osteonecrosis, myopathy, peptic ulcer disease, hypokalemia, osteoporosis, euphoria, psychosis, myasthenia gravis, growth suppression, and infections are possible complications of glucocorticoid use

Thrombolytics

The potential benefits of thrombolytics for the treatment of pulmonary embolism include fast dissolution of physiologically compromising pulmonary emboli, quickened recovery, prevention of recurrent thrombus formation, and rapid restoration of hemodynamic disturbances. For deep vein thrombosis, lysis of the thrombus can prevent pulmonary embolism and permanent pathologic changes, such as venous valvular dysfunction and postphlebitic syndrome.

Urokinase (Abbokinase)

Converts plasminogen to plasmin, which degrades fibrin clots, fibrinogen, and other plasma proteins.

Dosing

Adult

Loading dose: 4400 U/kg IV over 10 min and increase to 6000 U/kg/h
Maintenance dose: 4400-6000 U/kg/h IV

Pediatric

Loading and maintenance dose: Administer as in adults

Interactions

Thrombolytic enzymes; urokinase alone or in combination with anticoagulants and antiplatelet agents may increase risk of bleeding complications

Contraindications

Active internal bleeding; history of stroke; intracranial or intraspinal surgery within past 2 mo; intracranial neoplasm; trauma; CPR within past 10 d; bleeding diathesis; severe uncontrolled hypertension; hypersensitivity to albumin

Precautions

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Caution in patients receiving IM administration of medications, severe hypertension, and trauma or surgery in previous 10 d; avoid dislodging a possible deep vein thrombus, do not measure blood pressure in lower extremities; monitor therapy by performing PT, aPTT, TT, or fibrinogen approximately 4 h after initiation of therapy

Anticoagulants

In superior vena cava syndrome (SVCS), these agents are used mainly to prevent pulmonary embolism from superior vena cava (SVC) thrombus.

Heparin

Inhibits thrombosis by inactivating activated factor X and inhibiting conversion of prothrombin to thrombin.

Dosing

Adult

5000 U IV bolus, then infusion to maintain aPTT 2-3 times the reference range

Pediatric

Initial dose: 50 U/kg IV
Maintenance infusion: 15-25 U/kg/h IV
Increase dose by 2-4 U/kg/h IV q6-8h prn using aPTT results

Interactions

Digoxin, nicotine, tetracycline, and antihistamines may decrease effects; NSAIDs, ASA, dextran, dipyridamole, and hydroxychloroquine may increase toxicity

Contraindications

Documented hypersensitivity; subacute bacterial endocarditis; active bleeding; history of heparin-induced thrombocytopenia

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

IM use not recommended; bleeding or conditions with increased risk for bleeding and white clot syndrome are precautions; monitor aPTT and platelet counts

Warfarin (Coumadin)

Inhibits synthesis of vitamin K–dependent coagulation factors (factors II, VII, IX, X).

Dosing

Adult

Initial: 5-10 mg PO
Maintenance: 2-10 mg PO qd to maintain INR of 2-3

Pediatric

0.05-0.34 mg/kg/d PO; adjust dose according to desired INR

Interactions

Griseofulvin, carbamazepine, glutethimide, estrogens, nafcillin, phenytoin, rifampin, barbiturates, cholestyramine, colestipol, vitamin K, spironolactone, PO contraceptives, and sucralfate may decrease anticoagulant effects; PO antibiotics, phenylbutazone, salicylates, sulfonamides, chloral hydrate, clofibrate, diazoxide, anabolic steroids, ketoconazole, ethacrynic acid, miconazole, nalidixic acid, sulfonylureas, allopurinol, chloramphenicol, cimetidine, disulfiram, metronidazole, phenylbutazone, phenytoin, propoxyphene, sulfonamides, gemfibrozil, acetaminophen, and sulindac may increase anticoagulant effects

Contraindications

Documented hypersensitivity; hemorrhagic conditions; CNS, ophthalmic, or traumatic surgery; blood dyscrasias; malignant hypertension

Precautions

Pregnancy

X - Contraindicated; benefit does not outweigh risk

Precautions

Monitor PT/INR; caution in hepatic or renal failure, thyroid disorders, infections, trauma, diabetes mellitus, hypertension, protein C deficiency, and polycythemia vera

Follow-up

Further Inpatient Care

Admit the patient to the hospital if symptoms of superior vena cava syndrome (SVCS) are moderate to severe and/or when a patient requires the administration of thrombolytic therapy or anticoagulation.

Further Outpatient Care

• Instruct patients to use supportive measures, such as elevation of the head of the bed.
• Carefully monitor the patient's symptoms and the adverse effects of the administered treatment. Patients should notify the physician immediately if any change in symptoms occurs.

Inpatient & Outpatient Medications

• Oxygen supplementation may be provided if needed.
• Antiemetics may be provided as needed to prevent nausea and vomiting.
• For those patients started on steroids, taper steroids slowly, depending on the patient's condition.

Transfer

Transfer may be required for further diagnostic evaluation and surgical intervention.

Complications

Complications include laryngeal edema, cerebral edema, decreased cardiac output with hypotension, and pulmonary embolism (when an associated thrombus is present).

Prognosis

• The survival of patients with superior vena cava syndrome (SVCS) depends mainly on the course of the underlying disease.
• Untreated patients and those not responding to treatment survive approximately 30 days.

Miscellaneous

Medicolegal Pitfalls

• Failure to establish the correct diagnosis and the underlying etiology
• Failure to initiate immediate treatment
• Failure to recognize a thrombus in the superior vena cava (SVC)
• Failure to consult a medical oncologist and radiation therapist
• Failure to expeditiously diagnose and appropriately manage heparin-related complications
  • In particular, one must monitor platelet count and be vigilant should a rapid decline in platelets occur. This suggests the possibility of platelet-induced thrombocytopenia syndrome (white clot syndrome). This rare syndrome may lead to extremity gangrene and life-threatening venous thromboembolism.
  • Management requires urgent discontinuation of heparin and urgent evaluation by a hematologist for appropriate pharmacotherapy.
  • Vascular surgical evaluation may also be indicated.

Multimedia

Media file 1: Superior vena cava syndrome (case 1). The patient was a 35-year-old man with a 3-year history of progressive upper-extremity and fascial swelling. The patient had undergone treatment for histoplasmosis in the past. CT scan shows a narrowed superior vena cava with adjacent calcified lymph nodes and posterior soft tissue thickening.

Media file 2: Superior vena cava syndrome (case 1, cont'd). Sonogram shows markedly damped venous waveform with complete loss of normal venous pulsatility and minimal respiratory variation.

Media file 3: Superior vena cava syndrome (case 1, cont'd). Venogram shows almost complete occlusion of the superior vena cava with dramatic collateral drainage through the left superior intercostal vein.

Media file 4: Superior vena cava syndrome (case 1, cont'd). A Palmaz P308 stent mounted on a 12-mm balloon was deployed in the superior vena cava after it was predilated to 8 mm. The stent was subsequently dilated to 14 mm.

Media file 5: Superior vena cava syndrome (case 1, cont'd). Venogram obtained after stenting shows a widely patent superior vena cava with no collateral drainage. Pressure measurements after stenting showed a 1- to 2-mm residual gradient.

Media file 6: Superior vena cava syndrome (case 1, cont'd). Sonogram obtained 1 year after stenting shows near-normal venous pulsatility and respiratory phasicity. The patient experienced a complete resolution of symptoms.

References

1. National Cancer Institute. Cardiopulmonary syndromes. 2005;[Full Text].

2. Schechter MM. The superior vena cava syndrome. Am J Med Sci. Jan 1954;227(1):46-56. [Medline].

3. Flounders J. Superor vena cava syndrome. Oncol Nurs Forum. 2003;30(4):E84-8.

4. Ahmann FR. A reassessment of the clinical implications of the superior vena caval syndrome. J Clin Oncol. Aug 1984;2(8):961-9. [Medline].

5. Hassikou H, Bono W, Bahiri R, et al. Vascular involvement in Behçet's disease. Two case reports. Joint Bone Spine. Jun 2002;69(4):416-8. [Medline].

6. Hunter W. The history of an aneurysm of the aorta with some remarks on aneurysms in general. Med Obs Enq. 1757;1:323-357.

7. Armstrong BA, Perez CA, Simpson JR, et al. Role of irradiation in the management of superior vena cava syndrome. Int J Radiat Oncol Biol Phys. Apr 1987;13(4):531-9. [Medline].

8. Houman M, Ksontini I, Ben Ghorbel I, et al. Association of right heart thrombosis, endomyocardial fibrosis, and pulmonary artery aneurysm in Behçet's disease. Eur J Intern Med. Oct 2002;13(7):455. [Medline].

9. Salsali M, Cliffton EE. Superior vena caval obstruction in carcinoma of lung. N Y State J Med. Nov 15 1969;69(22):2875-80. [Medline].

10. Rice TW, Rodriguez RM, Light RW. The superior vena cava syndrome: clinical characteristics and evolving etiology. Medicine (Baltimore). Jan 2006;85(1):37-42. [Medline].

11. Blalock A, Cunningham RS, Robinson CS. Experimental production of chylothorax by occlusion of the superior vena cava. Ann Surg. Sep 1936;104(3):359-64. [Medline].

12. Escalante CP. Causes and management of superior vena cava syndrome. Oncology (Williston Park). Jun 1993;7(6):61-8; discussion 71-2, 75-7. [Medline].

13. Schraufnagel DE, Hill R, Leech JA, et al. Superior vena caval obstruction. Is it a medical emergency?. Am J Med. Jun 1981;70(6):1169-74. [Medline].

14. Klassen KP, Andrews NC, Curtis GM. Diagnosis and treatment of superior-vena-cava obstruction. AMA Arch Surg. Sep 1951;63(3):311-25. [Medline].

15. Sakura M, Tsujii T, Yamauchi A, et al. Superior vena cava syndrome caused by supraclavicular lymph node metastasis of renal cell carcinoma. Int J Clin Oncol. Oct 2007;12(5):382-4. [Medline].

16. Nieto AF, Doty DB. Superior vena cava obstruction: clinical syndrome, etiology, and treatment. Curr Probl Cancer. Sep 1986;10(9):441-84. [Medline].

17. Lochridge SK, Knibbe WP, Doty DB. Obstruction of the superior vena cava. Surgery. Jan 1979;85(1):14-24. [Medline].

18. Bigsby R, Greengrass R, Unruh H. Diagnostic algorithm for acute superior vena caval obstruction (SVCO). J Cardiovasc Surg (Torino). Aug 1993;34(4):347-50. [Medline].

19. Parish JM, Marschke RF Jr, Dines DE, et al. Etiologic considerations in superior vena cava syndrome. Mayo Clin Proc. Jul 1981;56(7):407-13. [Medline].

20. Marcy PY, Magne N, Bentolila F, et al. Superior vena cava obstruction: is stenting necessary?. Support Care Cancer. Mar 2001;9(2):103-7. [Medline].

21. Akoglu H, Yilmaz R, Peynircioglu B, et al. A rare complication of hemodialysis catheters: superior vena cava syndrome. Hemodial Int. Oct 2007;11(4):385-91. [Medline].

22. Scarantino C, Salazar OM, Rubin P, et al. The optimum radiation schedule in treatment of superior vena caval obstruction: importance of 99mTc scintiangiograms. Int J Radiat Oncol Biol Phys. Nov-Dec 1979;5(11-12):1987-95. [Medline].

23. Abner A. Approach to the patient who presents with superior vena cava obstruction. Chest. Apr 1993;103(4 Suppl):394S-397S. [Medline].

24. Dosios T, Theakos N, Chatziantoniou C. Cervical mediastinoscopy and anterior mediastinotomy in superior vena cava obstruction. Chest. Sep 2005;128(3):1551-6. [Medline].

25. Rowell NP, Gleeson FV. Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus: a systematic review. Clin Oncol (R Coll Radiol). Oct 2002;14(5):338-51. [Medline].

26. Urban T, Lebeau B, Chastang C, et al. Superior vena cava syndrome in small-cell lung cancer. Arch Intern Med. Feb 8 1993;153(3):384-7. [Medline].

27. Maddox AM, Valdivieso M, Lukeman J, et al. Superior vena cava obstruction in small cell bronchogenic carcinoma. Clinical parameters and survival. Cancer. Dec 1 1983;52(11):2165-72. [Medline].

28. Perez-Soler R, McLaughlin P, Velasquez WS, et al. Clinical features and results of management of superior vena cava syndrome secondary to lymphoma. J Clin Oncol. Apr 1984;2(4):260-6. [Medline].

29. Adelstein DJ, Hines JD, Carter SG, et al. Thromboembolic events in patients with malignant superior vena cava syndrome and the role of anticoagulation. Cancer. Nov 15 1988;62(10):2258-62. [Medline].

30. Watkinson AF, Yeow TN, Fraser C. Endovascular stenting to treat obstruction of the superior vena cava. BMJ. Jun 21 2008;336(7658):1434-7. [Medline].

31. Garcia Monaco R, Bertoni H, Pallota G, et al. Use of self-expanding vascular endoprostheses in superior vena cava syndrome. Eur J Cardiothorac Surg. Aug 2003;24(2):208-11. [Medline].

32. Smayra T, Otal P, Chabbert V, et al. Long-term results of endovascular stent placement in the superior caval venous system. Cardiovasc Intervent Radiol. Nov-Dec 2001;24(6):388-94. [Medline].

33. Thony F, Moro D, Witmeyer P, et al. Endovascular treatment of superior vena cava obstruction in patients with malignancies. Eur Radiol. 1999;9(5):965-71. [Medline].

34. Yim CD, Sane SS, Bjarnason H. Superior vena cava stenting. Radiol Clin North Am. Mar 2000;38(2):409-24. [Medline].

35. Garlitski AC, Swingle JD, Aizer A, et al. Percutaneous treatment of the superior vena cava syndrome via an excimer laser sheath in a patient with a single chamber atrial pacemaker. J Interv Card Electrophysiol. Sep 2006;16(3):203-6. [Medline].

36. Nunnelee JD. Superior vena cava syndrome. J Vasc Nurs. Mar 2007;25(1):2-5; quiz 6. [Medline].

37. Rice TW. Pleural effusions in superior vena cava syndrome: prevalence, characteristics, and proposed pathophysiology. Curr Opin Pulm Med. Jul 2007;13(4):324-7. [Medline].

38. Vogelzang R, Schindler N. Superor vena cava syndrome: endovascular therapy. In: Gloviczki P, Yoa J, eds. Handbook of venous disorders. (2nd ed). London: Arnold; 2001:401-7.

Keywords

super vena cava syndrome, SVCS, superior vena cava, SVC syndrome, SVC obstruction, superior vena cava obstruction, syphilitic aneurysms, tuberculous mediastinitis, lung cancer, vena cava

Contributor Information and Disclosures

Author

Todd A Nickloes, DO, Assistant Professor of Surgery, Division of Trauma/Critical Care, University of Tennessee Medical Center
Todd A Nickloes, DO is a member of the following medical societies: American College of Osteopathic Surgeons, American Medical Association, American Osteopathic Association, Association for Academic Surgery, Eastern Association for the Surgery of Trauma, Society of Critical Care Medicine, Society of Laparoendoscopic Surgeons, Southeastern Surgical Congress, and Southern Medical Association
Disclosure: Nothing to disclose.

Coauthor(s)

LaMar O Mack, MD, Staff Physician, Department of Surgery, University of Tennessee Medical Center
LaMar O Mack, MD is a member of the following medical societies: American Urological Association, National Medical Association, and Student National Medical Association
Disclosure: Nothing to disclose.

Andre M Kallab, MD, Clinical Associate Professor of Oncology, Medical College of Georgia; Consulting Staff, Department of Oncology, Northeast Georgia Diagnostic Clinic
Andre M Kallab, MD is a member of the following medical societies: American College of Physicians, American Medical Association, and American Society of Hematology
Disclosure: Nothing to disclose.

Medical Editor

Richard M Stillman, MD, FACS, Honorary Medical Staff, Northwest Medical Center; Former Chief of Staff and Medical Director, Wound Healing Center, Department of Surgery, Northwest Medical Center
Richard M Stillman, MD, FACS is a member of the following medical societies: American College of Angiology, American College of Surgeons, Association for Academic Surgery, and Society of University Surgeons
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Vincent Lopez Rowe, MD, Assistant Professor of Surgery, Department of Surgery, Division of Vascular Surgery, University of Southern California Medical Center
Vincent Lopez Rowe, MD is a member of the following medical societies: American College of Surgeons, Association for Academic Surgery, Peripheral Vascular Surgery Society, Society for Clinical Vascular Surgery, and Society for Vascular Surgery
Disclosure: Nothing to disclose.

CME Editor

Paolo Zamboni, MD, Professor of Surgery, Chief of Day Surgery Unit, Chair of Vascular Diseases Center, University of Ferrara, Italy
Paolo Zamboni, MD is a member of the following medical societies: American Venous Forum and New York Academy of Sciences
Disclosure: Nothing to disclose.

Chief Editor

William H Pearce, MD, Chief, Division of Vascular Surgery, Violet and Charles Baldwin Professor of Vascular Surgery, Department of Surgery, Northwestern University School of Medicine
William H Pearce, MD is a member of the following medical societies: American College of Surgeons, American Heart Association, American Surgical Association, Association for Academic Surgery, Association of VA Surgeons, Central Surgical Association, New York Academy of Sciences, Society for Vascular Surgery, Society of Critical Care Medicine, Society of University Surgeons, and Western Surgical Association
Disclosure: Nothing to disclose.

© 1994- by Medscape.
All Rights Reserved
(http://www.medscape.com/public/copyright)